Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.28 USD
Change Today -0.07 / -1.10%
Volume 244.3K
CYTK On Other Exchanges
As of 8:10 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

cytokinetics inc (CYTK) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/17/15 - $8.61
52 Week Low
10/13/14 - $3.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYTOKINETICS INC (CYTK)

cytokinetics inc (CYTK) Related Businessweek News

No Related Businessweek News Found

cytokinetics inc (CYTK) Details

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is involved in developing Tirasemtiv, a fast skeletal troponin activator that is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107 that is in Phase I for the treatment of spinal muscle atrophy; and Omecamtiv mecarbil, which is in Phase II clinical trials for the potential treatment of heart failure. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to advance novel therapies for diseases and medical conditions associated with muscle weakness. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

92 Employees
Last Reported Date: 03/6/15
Founded in 1997

cytokinetics inc (CYTK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $555.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $401.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $388.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $384.6K
Senior Vice President of Human Resources
Total Annual Compensation: $285.0K
Compensation as of Fiscal Year 2014.

cytokinetics inc (CYTK) Key Developments

Cytokinetics Presents Results from Phase I Studies of CK-2127107

Cytokinetics announced that results from three double-blind, randomized, placebo-controlled Phase I studies of CK-2127107 in healthy volunteers were presented in a poster at the 19th International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference at the Westin Crown Center in Kansas City, MO. In a pharmacodynamic study that was designed to assess the translation of the mechanism of CK-2127107 to humans, treatment with the fast skeletal muscle activator increased muscle force produced by the tibialis anterior muscle in response to nerve stimulation. Cytokinetics is developing CK-2127107 in collaboration with Astellas Pharma Inc.

Cytokinetics, Incorporated - Analyst/Investor Day

Cytokinetics, Incorporated - Analyst/Investor Day

Cytokinetics, Incorporated Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cytokinetics, Incorporated reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $4,414,000 compared to $7,979,000 a year ago. Net loss was $8,872,000 or $0.23 per basic share and diluted share compared to a net loss of $8,744,000, or $0.27 per basic and diluted share. Operating loss was $8,909,000 against $8,770,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTK:US $6.28 USD -0.07

CYTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.62 USD -0.01
CTI BioPharma Corp $1.95 USD -0.02
Curis Inc $3.42 USD +0.09
Evotec AG €3.21 EUR -0.052
Exelixis Inc $3.51 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOKINETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at